South Korea · Delayed Price · Currency is KRW Meta Biomed Statistics
Total Valuation
Meta Biomed has a market cap or net worth of KRW 106.92 billion. The enterprise value is 113.83 billion.
| Market Cap | 106.92B |
| Enterprise Value | 113.83B |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | Jun 29, 2026 |
Share Statistics
Meta Biomed has 27.17 million shares outstanding. The number of shares has decreased by -8.37% in one year.
| Current Share Class | 27.17M |
| Shares Outstanding | 27.17M |
| Shares Change (YoY) | -8.37% |
| Shares Change (QoQ) | +0.53% |
| Owned by Insiders (%) | 22.47% |
| Owned by Institutions (%) | 5.68% |
| Float | 21.07M |
Valuation Ratios
The trailing PE ratio is 10.98 and the forward PE ratio is 5.84.
| PE Ratio | 10.98 |
| Forward PE | 5.84 |
| PS Ratio | 1.07 |
| PB Ratio | 0.84 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 6.27 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 11.64 |
| EV / Sales | 1.14 |
| EV / EBITDA | 4.25 |
| EV / EBIT | 5.41 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.55, with a Debt / Equity ratio of 0.35.
| Current Ratio | 1.55 |
| Quick Ratio | 1.08 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | 1.69 |
| Debt / FCF | -31.49 |
| Interest Coverage | 8.68 |
Financial Efficiency
Return on equity (ROE) is 8.34% and return on invested capital (ROIC) is 12.96%.
| Return on Equity (ROE) | 8.34% |
| Return on Assets (ROA) | 6.94% |
| Return on Invested Capital (ROIC) | 12.96% |
| Return on Capital Employed (ROCE) | 15.12% |
| Weighted Average Cost of Capital (WACC) | 6.46% |
| Revenue Per Employee | 317.42M |
| Profits Per Employee | 31.15M |
| Employee Count | 314 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 2.25 |
Taxes
In the past 12 months, Meta Biomed has paid 1.84 billion in taxes.
| Income Tax | 1.84B |
| Effective Tax Rate | 16.24% |
Stock Price Statistics
The stock price has decreased by -26.86% in the last 52 weeks. The beta is 0.55, so Meta Biomed's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | -26.86% |
| 50-Day Moving Average | 3,840.80 |
| 200-Day Moving Average | 4,750.23 |
| Relative Strength Index (RSI) | 55.88 |
| Average Volume (20 Days) | 145,539 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Meta Biomed had revenue of KRW 99.67 billion and earned 9.78 billion in profits. Earnings per share was 358.29.
| Revenue | 99.67B |
| Gross Profit | 53.37B |
| Operating Income | 20.43B |
| Pretax Income | 11.36B |
| Net Income | 9.78B |
| EBITDA | 26.17B |
| EBIT | 20.43B |
| Earnings Per Share (EPS) | 358.29 |
Balance Sheet
The company has 37.75 billion in cash and 44.24 billion in debt, with a net cash position of -6.49 billion or -238.73 per share.
| Cash & Cash Equivalents | 37.75B |
| Total Debt | 44.24B |
| Net Cash | -6.49B |
| Net Cash Per Share | -238.73 |
| Equity (Book Value) | 127.95B |
| Book Value Per Share | 4,693.30 |
| Working Capital | 29.98B |
Cash Flow
In the last 12 months, operating cash flow was 17.06 billion and capital expenditures -18.47 billion, giving a free cash flow of -1.40 billion.
| Operating Cash Flow | 17.06B |
| Capital Expenditures | -18.47B |
| Depreciation & Amortization | 5.74B |
| Net Borrowing | -5.15B |
| Free Cash Flow | -1.40B |
| FCF Per Share | -51.69 |
Margins
Gross margin is 53.55%, with operating and profit margins of 20.50% and 9.81%.
| Gross Margin | 53.55% |
| Operating Margin | 20.50% |
| Pretax Margin | 11.40% |
| Profit Margin | 9.81% |
| EBITDA Margin | 26.25% |
| EBIT Margin | 20.50% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 105.00, which amounts to a dividend yield of 2.67%.
| Dividend Per Share | 105.00 |
| Dividend Yield | 2.67% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | n/a |
| Buyback Yield | 8.37% |
| Shareholder Yield | 11.04% |
| Earnings Yield | 9.15% |
| FCF Yield | -1.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 23, 2010. It was a forward split with a ratio of 2.
| Last Split Date | Apr 23, 2010 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Meta Biomed has an Altman Z-Score of 2.83 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.83 |
| Piotroski F-Score | 6 |